With the reality of Brexit already impacting the UK’s clinical trials environment, Zamas Lam (QPS; DE, USA) discusses the effect this will have on bioanalytical research, and suggests 10 questions to ask when relocating UK-based preclinical and bioanalysis research projects.
“There are, in essence, two schools of thought that I can perceive when discussions occur on the topic of appropriate purity of the laboratory water and various solvents, additives and reagents for any given stage of a quantitative bioanalytical procedure.” Find out more from Robert MacNeill (Envigo) in this editorial column.
Biomedical research is largely centered on making new discoveries as it relates to human health and disease. The ultimate goal is to understand how human biology works and when and why it goes awry. With a strong foundation on the mechanisms of health and disease, advances in diagnostics and therapeutic interventions can be generated bringing cures to recalcitrant diseases such as cancer and neurodegenerative pathologies.
In this editorial, Robert MacNeill (Envigo) dicusses the case for the surrogate analyte approach for biomarker validation.
Read time: 3:45 mins
Find out more about the immunogenicity of antibody–drug conjugates (ADCs) in this column from Corinna Fiorotti, Business Development Director at BioAgilytix (NC, USA).
Read time: 4:30 mins
In this column, Afshin Safavi differentiates between ‘assay qualification’ and ‘assay validation’ explaining current industry guidance, the translation of this guidance into the exploratory biomarker world, and how BioAgilytix (NC, USA) approaches these challenges.
Quantitative whole body autoradiography (QWBA) and imaging mass spectrometry (IMS): can IMS replace QWBA to support regulated drug discovery and development
Read time: 4:45 mins
Eric Solon (Madrigal Pharmaceuticals; PA, USA) discusses whether or not IMS can replace QWBA as the technique of choice when examining the disposition of new drug and biotherapeutic entities.